1. Home
  2. MLYS vs VVX Comparison

MLYS vs VVX Comparison

Compare MLYS & VVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$30.36

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo V2X Inc.

VVX

V2X Inc.

HOLD

Current Price

$75.66

Market Cap

2.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
VVX
Founded
2019
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Diversified Commercial Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.2B
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
MLYS
VVX
Price
$30.36
$75.66
Analyst Decision
Strong Buy
Hold
Analyst Count
7
8
Target Price
$48.67
$69.88
AVG Volume (30 Days)
998.0K
379.6K
Earning Date
05-06-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
37.43
126.85
EPS
N/A
0.60
Revenue
N/A
$4,480,038,000.00
Revenue This Year
N/A
$7.81
Revenue Next Year
N/A
$5.84
P/E Ratio
N/A
$126.13
Revenue Growth
N/A
3.65
52 Week Low
$12.59
$43.42
52 Week High
$47.65
$78.36

Technical Indicators

Market Signals
Indicator
MLYS
VVX
Relative Strength Index (RSI) 60.98 69.68
Support Level $26.85 $66.12
Resistance Level $31.19 N/A
Average True Range (ATR) 1.59 2.74
MACD 0.18 1.14
Stochastic Oscillator 84.81 84.44

Price Performance

Historical Comparison
MLYS
VVX

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About VVX V2X Inc.

V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.

Share on Social Networks: